Inhibitors of IL-23 are clinically approved for the treatment of psoriasis and inflammatory bowel disease43,44, and inhibitors of IL-17A are used in the treatment of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis45. Here, IL17A is linked to psoriasis vulgaris.